Clinical Trials · NCT05207709
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- SOLTI Breast Cancer Research Group
- Enrollment
- 61
- Start date
- Mar 2022
- Locations
- 71 sites, 3 countries
- Primary endpoint
- Progression-free survival